Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results.
Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Mazur R, Ghelani P, Forrer P, Wraith L, Patekar M. Magnolo N, et al. Among authors: forrer p. J Am Acad Dermatol. 2022 Jan;86(1):122-130. doi: 10.1016/j.jaad.2021.08.066. Epub 2021 Sep 30. J Am Acad Dermatol. 2022. PMID: 34555481 Clinical Trial.
Efficacy of Secukinumab Across Subgroups and Overall Safety in Pediatric Patients with Moderate to Severe Plaque Psoriasis: Week 52 Results from a Phase III Randomized Study.
Magnolo N, Kingo K, Laquer V, Browning J, Reich A, Szepietowski JC, Keefe D, Papanastasiou P, Bao W, Forrer P, Patekar M. Magnolo N, et al. Among authors: forrer p. Paediatr Drugs. 2022 Jul;24(4):377-387. doi: 10.1007/s40272-022-00507-0. Epub 2022 Jun 13. Paediatr Drugs. 2022. PMID: 35698000 Free PMC article. Clinical Trial.
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials.
Sticherling M, Nikkels AF, Hamza AM, Kwong P, Szepietowski JC, El Sayed M, Ghislain PD, Khotko AA, Patekar M, Ortmann CE, Forrer P, Papanastasiou P, Keefe D. Sticherling M, et al. Among authors: forrer p. Am J Clin Dermatol. 2023 Sep;24(5):821-835. doi: 10.1007/s40257-023-00782-8. Epub 2023 Jun 21. Am J Clin Dermatol. 2023. PMID: 37341961 Free PMC article.
Unveiling signaling pathways inducing MHC class II expression in neutrophils.
Forrer P, Palianina D, Stühler C, Kreuzaler M, Roux J, Li J, Schmutz C, Burckhardt D, Franzeck F, Finke D, Schmidt A, Bumann D, Khanna N. Forrer P, et al. Front Immunol. 2024 Sep 30;15:1444558. doi: 10.3389/fimmu.2024.1444558. eCollection 2024. Front Immunol. 2024. PMID: 39403371 Free PMC article.
Half-life extension using serum albumin-binding DARPin® domains.
Steiner D, Merz FW, Sonderegger I, Gulotti-Georgieva M, Villemagne D, Phillips DJ, Forrer P, Stumpp MT, Zitt C, Binz HK. Steiner D, et al. Among authors: forrer p. Protein Eng Des Sel. 2017 Sep 1;30(9):583-591. doi: 10.1093/protein/gzx022. Protein Eng Des Sel. 2017. PMID: 29088432
Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation and Association With Occurrence and Outcome of Invasive Aspergillosis.
Stuehler C, Kuenzli E, Jaeger VK, Baettig V, Ferracin F, Rajacic Z, Kaiser D, Bernardini C, Forrer P, Weisser M, Elzi L, Battegay M, Halter J, Passweg J, Khanna N. Stuehler C, et al. Among authors: forrer p. J Infect Dis. 2015 Sep 15;212(6):959-67. doi: 10.1093/infdis/jiv143. Epub 2015 Mar 6. J Infect Dis. 2015. PMID: 25748323
47 results